MCRI and Incepta Pharmaceuticals partner to protect children from rotavirus
Posted: 4 June 2024 Murdoch Children’s Research Institute (MCRI) and Incepta Pharmaceuticals, based in Bangladesh, have embarked on a collaboration aimed at bringing life-saving innovation to the global healthcare landscape. MCRI has announced the signing of a non-exclusive licensing…
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial
Posted: 4 June 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announced that it has entered into a clinical trial collaboration and…
Amplia establishes world class Clinical Advisory Board
Posted: 3 June 2024 Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce the appointment of five key opinion leaders and clinical oncologists to its Clinical Advisory Board (CAB). The CAB will provide expert…
DIMERIX AND TAIBA ENTER INTO AN EXCLUSIVE LICENSE AGREEMENT TO COMMERCIALISE DMX-200 IN THE MIDDLE EAST
Posted: 28 May 2024 Dimerix Limited (ASX: DXB, “Dimerix”) and Taiba Middle East FZ LLC, (“Taiba”), today announced that they have entered into an exclusive license agreement for the commercialisation of Dimerix’ Phase 3 drug candidate DMX-200 for…
Hydrix signs $2.3m contract with European medical technology company
Posted: 28 May 2024 Hydrix Limited (Hydrix or the Company) (ASX: HYD) is pleased to announce its wholly-owned subsidiary Hydrix Services has entered into a $2.3m contract with leading European medical company Paul Hartmann AG (Hartmann) (Contract). Under…
Starpharma announces positive final DEP® irinotecan Phase 2 clinical trial results
Posted: 28 May 2024 Starpharma (ASX: SPL, OTCQX: SPHRY), dedicated to helping patients with significant illnesses, such as cancer, achieve improved health outcomes through the application of our unique dendrimer technology, today announces the full results of the Phase…
Phase 2 trial shows significant improvements in Pitt Hopkins syndrome
Posted: 28 May 2024 Neuren Pharmaceuticals (ASX: NEU) today announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Pitt Hopkins syndrome (PTHS). Statistically significant improvement from baseline was observed by both clinicians and…
Adherium will provide its Hailie Smartinhaler for an AstraZeneca clinical trial
Posted: 27 May 2024 Adherium Limited (“Adherium” or “the Company”; ASX:ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, today announced that AstraZeneca has selected its Hailie® Smartinhaler® platform for a clinical trial. This contract…
Neo-Bionica Announces the Appointment of Stéphane Chatonsky and Dr Colin White to its Board of Directors
Posted: 27 May 2024 Neo-Bionica welcomes two new non-executive directors with extensive international and business experience, to its board. Stéphane and Colin bring expertise that supports and strengthens Neo-Bionica’s domestic and international expansion plans. Stéphane Chatonsky, MBA, GAICD…
Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer
Posted: 24 May 2024 Telix today announces the successful completion of CUPID1, a first-in-human Phase I dose escalation study of TLX592 in patients with advanced prostate cancer. TLX592 (225Ac-PSMA-RADmAb®) is Telix’s investigational “next generation” targeted alpha therapy (TAT)…
Pancreatic cancer research receives $8m philanthropic funding boost
Posted: 24 May 2024 An exceptional $8 million, 10-year philanthropic investment will spearhead new treatments for pancreatic cancer and create a new dedicated research centre at WEHI. The centre, to be established thanks to an investment by Australian…
CARTHERICS GRANTED EUROPEAN PATENT FOR MULTIPLE DEVELOPMENT CANDIDATES
Posted: 24 May 2024 Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has been granted its second European Patent from the family…
